Dragonfly to receive a $12 million payment and is eligible to receive potential future milestones and royalties on net sales. WALTHAM, Massachusetts, Aug. 10, 2020 /PRNewswire/ -- Dragonfly ...
Bristol Myers Squibb will pay $475 million to license an experimental cytokine drug from Dragonfly Therapeutics. The therapy, called DF6002, is an IL-12 immunoglobulin Fc fusion protein. IL-12 helps ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Bristol Myers Squibb (BMS) has inked a deal with Dragonfly Therapeutic for an exclusive license to its interleukin-12 immunotherapy programme. BMS will pay Dragonfly $245m upfront, with the further ...
Bristol Myers Squibb is paying nearly half a billion in near-term and upfronts to licence Dragonfly Therapeutics’ interleukin-12 (IL-12) immunotherapy program. This program is the early-stage ...
Dragonfly Therapeutics Inc, announced that Bristol Myers Squibb has licensed its fourth TriNKET immunotherapy drug candidate from Dragonfly, a clinical-stage biopharmaceutical company. Since the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results